Table 2.

Characteristics and course of chronic thrombocytopaenia in common variable immunodeficiency (CVID) patients

Patient number	1	2	3	4	5	6	7
Gender	boy	boy	boy	girl	boy	boy	boy
Age of diagnosis: thrombocytopaenia	14 years	4 years	4 years 10 months	8 years	11 years	7 years	13 years
Therapy of thrombocytopaenia	steroids (pulses)	IVIG 1.0 g/kg b.w. steroids, azathioprine	steroids, azathioprine, IVIG 1.0 g/kg b.w.	steroids	steroids, IVIG 1.0 g/kg b.w.	steroids	steroids
Complications, other symptoms	no	no	severe haemolytic anaemia (Evans syndrome)	diabetes, severe overweight	no	no
Lowest number of platelets (/ul)	28 000	0	0	0	27 000	20 000	37 000
Number of platelets at beginning of IVIG (/ul)	253 000	156 000	133 000	15 000	27 000	87 000	126 000
Mean dose of IVIG (g/kg b.w./monthj	0.43-0.38	0.36-0.45	0.35-0.42	0.35-0.45	0.38-0.3	0.4-0.35	0.42-0.50
Mean number of platelets during IVIG (/Ml) (range)	149 100 (120 000-196 000)	123 000 (57 000-198 000)	131 000 (97 000-154 000)	51 460 (18 000-68 000)	113 500 (56 000-154 000)	172 400 (99 000-264 000)	112 700 (86 000-133 000)
Episodes of exacerbations of thrombocytopaenia during IVIG	1	0	3 (1 severe)	4	1 severe	0	0
Therapy of thrombocytopaenia exacerbations	IVIG 1.0 g/kg b.w. steroids		steroids, platelets, erythrocytes and plasma transfusions, plasmapheresis	IVIG 1.0 g/kg b.w	steroids, splenectomy
Time of observation	12 years	2 years	7 years	4 years	5 years	4 years	11 years